Novartis
NVS
1,094 hedge funds and large institutions have $23.5B invested in Novartis in 2019 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 180 increasing their positions, 853 reducing their positions, and 84 closing their positions.
90% more call options, than puts
Call options by funds: $228M | Put options by funds: $120M
1.89% less ownership
Funds ownership: 11.97% → 10.08% (-1.9%)
3% less funds holding
Funds holding: 1,133 → 1,094 (-39)
11% less capital invested
Capital invested by funds: $26.2B → $23.5B (-$2.77B)
26% less funds holding in top 10
Funds holding in top 10: 39 → 29 (-10)
27% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 84
79% less repeat investments, than reductions
Existing positions increased: 180 | Existing positions reduced: 853
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$83.3M |
| 2 |
Renaissance Technologies
New York
|
+$40.8M |
| 3 |
SC
Samlyn Capital
New York
|
+$36.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$33M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$31.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$942M |
| 2 |
BlackRock
New York
|
-$536M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$278M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$204M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$186M |
NVS Hedge Fund Activity: Q2 2019 in Review
1,094 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2019, worth a combined $23.5B — down 11% from $26.2B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of NVS and 61 opened new positions — a net loss of 23 holders — while 853 trimmed existing stakes and 180 added.
The largest buyer was Bain Capital Public Equity Management II, opening a new position worth an estimated $83.3M. The largest seller was Dodge & Cox, cutting an estimated $942M.
- 1,094 institutional investors held Novartis (NVS) as of Q2 2019, down from 1,133 in Q1 2019.
- Funds reported $23.5B of Novartis stock for Q2 2019, down 11% quarter-over-quarter.
- 61 funds opened new Novartis positions in Q2 2019 and 84 closed out, a net change of -23 holders.
- The largest Novartis buyer in Q2 2019 was Bain Capital Public Equity Management II, an estimated $83.3M added.
- The largest Novartis seller in Q2 2019 was Dodge & Cox, an estimated $942M sold.
Based on aggregated 13F filings for Q2 2019.